Burkina Faso vs Viet Nam: Average cost of tuberculosis treatment by type
Burkina Faso
13 constant 2022 US$
in 2024
Viet Nam
14 constant 2022 US$
in 2024
Burkina Faso rank
42nd
Viet Nam rank
40th
Average cost of tuberculosis treatment by type over time
- Burkina Faso
- Viet Nam
How they compare
Viet Nam currently reports 14 constant 2022 US$ against 13 constant 2022 US$ in Burkina Faso, a difference of 1 constant 2022 US$.
That makes Viet Nam's figure about 1.1 times Burkina Faso's.
The two have swapped places 3 times across 6 shared years of data; in 2019 it was Burkina Faso ahead.
Burkina Faso ranks 42nd and Viet Nam ranks 40th of 62 countries.
Burkina Faso has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Burkina Faso | Viet Nam | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 28 constant 2022 US$ | 7 constant 2022 US$ | 21 constant 2022 US$ | Burkina Faso |
| 2020s | 26.4 constant 2022 US$ | 24.4 constant 2022 US$ | 2 constant 2022 US$ | Burkina Faso |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of tuberculosis treatment by type, Burkina Faso or Viet Nam?
- Viet Nam, at 14 constant 2022 US$ against 13 constant 2022 US$ in Burkina Faso as of 2024.
- What is the difference in average cost of tuberculosis treatment by type between Burkina Faso and Viet Nam?
- 1 constant 2022 US$, with Viet Nam ahead.
- How many years of comparable data are there for Burkina Faso and Viet Nam?
- 6 years are reported by both, from 2019 to 2024.
- How do Burkina Faso and Viet Nam rank globally for average cost of tuberculosis treatment by type?
- Burkina Faso ranks 42nd and Viet Nam ranks 40th of 62 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of tuberculosis treatment by type. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per person starting tuberculosis preventive treatment, excluding buffer stock.